ArriVent BioPharma, Inc. (NASDAQ: AVBP) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.
ArriVent BioPharma Reports First Quarter 2024 Financial Results [Yahoo! Finance]
ArriVent BioPharma Reports First Quarter 2024 Financial Results
ArriVent BioPharma, Inc. (NASDAQ: AVBP) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $25.00 price target on the stock.
ArriVent Appoints Kristine Peterson to its Board of Directors